Flowvium
Retour à l'explorateur

CVS Health Corporation

CVSintermediary

CVS Health is one of the largest healthcare companies in the US, operating an integrated model spanning pharmacy benefits management (Caremark), health insurance (Aetna), retail pharmacy (9,900 stores), and primary care clinics (Oak Street Health, MinuteClinic).

Partager:
Compare

Produits et revenus

Part de revenus par produit

Répartition du chiffre d'affaires ($357B)

Données statiques (chargement des finances en temps réel…)

Health Services (Caremark PBM) (38%)
Health Insurance (Aetna) (35%)
Pharmacy & Consumer Wellness (22%)
Corporate / Other (5%)

Composition des segments et principaux clients

Détails du produit

Pharmacy Benefits (CVS Caremark)38%

One of the three largest pharmacy benefit managers (PBMs) in the US. Manages drug coverage for 100M+ plan members.

Health Insurance (Aetna)35%

Aetna commercial, Medicare Advantage, and Medicaid health plans serving 24M+ members acquired for $69B in 2018.

Retail Pharmacy (CVS Pharmacy)22%

9,900+ retail pharmacy locations. Filling 1.5B+ prescriptions annually. Also includes front-store retail.

Health Services (MinuteClinic / Oak Street)5%

Primary care clinics (1,100+ MinuteClinics, 200+ Oak Street Health centers). Vertical integration into care delivery.

Contexte macro et de marché

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Prochains catalyseurs

CMS 메디케어 최종 수가 발표 (2026.Q2)UNH/HUM/CVS Q1 실적 (2026.04)IRA 약가 협상 2차 품목 공개

Actualités récentes

Chargement des nouvelles...

Analyse IA

Cliquez sur « Obtenir l'analyse IA » pour une analyse de la chaîne d'approvisionnement de CVS Health Corporation par intelligence artificielle.

Informations sur l'entreprise

Siège social

Woonsocket, Rhode Island, USA

Fondée en

1963

Effectifs

300,000+

Aperçu du secteur헬스케어

Actualités du secteur

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Thèmes clés

  • CMS 메디케어 어드밴티지 수가 인하 → 보험사 마진 압박
  • AI 영상진단·병리학 도입 가속 — Tempus, Veracyte 수혜
  • GLP-1 보험 적용 확대 논의 → UNH·CVS 비용 증가 리스크

Prochains catalyseurs

  • CMS 메디케어 최종 수가 발표 (2026.Q2)
  • UNH/HUM/CVS Q1 실적 (2026.04)